PRMT1 methylates RIP3 to inhibit RIP1-RIP3 complex formation, resulting in the impaired RIP3 phosphorylation and necroptosis activation that builds the beneficial immune microenvironment against colon cancer growth (Fig. 5J). Here, PRMT1 is linked to malignant colon neoplasm.